File Download

There are no files associated with this item.

  • Find it @ UNIST can give you direct access to the published full text of this article. (UNISTARs only)
Related Researcher

김은희

Kim, Eunhee
Read More

Views & Downloads

Detailed Information

Cited time in webofscience Cited time in scopus
Metadata Downloads

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Author(s)
Durham, Benjamin H.Getta, BartlomiejDietrich, SaschaTaylor, JustinWon, HelenBogenberger, James M.Scott, SasinyaKim, EunheeChung, Young RockChung, Stephen S.Huellein, JenniferWalther, TatjanaWang, LuLu, Sydney X.Oakes, Christopher C.Tibes, RaoulHaferlach, TorstenTaylor, Barry S.Tallman, Martin S.Berger, Michael F.Park, Jae H.Zenz, ThorstenAbdel-Wahab, Omar
Issued Date
2017-10
DOI
10.1182/blood-2017-01765107
URI
https://scholarworks.unist.ac.kr/handle/201301/22868
Fulltext
http://www.bloodjournal.org/content/130/14/1644?sso-checked=true
Citation
BLOOD, v.130, no.14, pp.1644 - 1648
Abstract
Classical hairy cell leukemia (cHCL) is characterized by a near 100% frequency of the BRAFV600E mutation, whereas similar to 30% of variant HCLs (vHCLs) have MAP2K1 mutations. However, recurrent genetic alterations cooperating with BRAFV600E or MAP2K1 mutations in HCL, as well as those in MAP2K1 wild-type vHCL, are not well defined. We therefore performed deep targeted mutational and copy number analysis of cHCL (n553) and vHCL (n 5 8). The most common genetic alteration in cHCL apart from BRAFV600E washeterozygous loss of chromosome7q, the minimally deleted region of which targeted wild-type BRAF, subdividing cHCL into those hemizygous versus heterozygous for the BRAFV600E mutation. In addition to CDKN1B mutations in cHCL, recurrent inactivating mutations in KMT2C (MLL3) were identified in 15% and 25% of cHCLs and vHCLs, respectively. Moreover, 13% ofvHCLsharbored predicted activating mutations inCCND3. Achange-of-function mutation in the splicing factorU2AF1was also present in13% of vHCLs. Genomic analysis of de novo vemurafenib-resistant cHCL identified a novel gain-of-function mutation in IRS1 and losses of NF1 and NF2, each ofwhich contributed to resistance. These data provide further insight into the genetic bases of cHCL and vHCL and mechanisms of RAF inhibitor resistance encountered clinically.
Publisher
AMER SOC HEMATOLOGY
ISSN
0006-4971
Keyword
MUTATIONSBRAFSENESCENCETARGETSASSAY

qrcode

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.